DR. JAMES H ESSELL MD NPI 1265425078

NPI Details

DR. James H Essell, MD is a hematology and oncology internal medicine in Cincinnati, OH with 41 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. James H Essell, MD NPI is 1265425078. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE
Graduation Year:1985

The provider's business location address is:

4777 E GALBRAITH RD
STE 320
CINCINNATI, OH
ZIP 45236-725
Phone: (513) 751-2273
Fax: (513) 793-6290

The NPI 1265425078 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS:Q5101)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, decitabine, 1 mg (HCPCS:J0894)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Unclassified drugs (HCPCS:J3490)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Magnesium level (HCPCS:83735)
• Blood test, clotting time (HCPCS:85610)
• Ferritin (blood protein) level (HCPCS:82728)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Phosphate level (HCPCS:84100)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Uric acid level, blood (HCPCS:84550)
• Injection of drug or substance into vein (HCPCS:96374)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Hospital discharge day management, more than 30 minutes (HCPCS:99239)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0220)
• Folic acid level, serum (HCPCS:82746)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 8/26/2005 and was last updated on 4/22/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.